Briefing
MRD-guided maintenance after transplant in FLT3-ITD acute myeloid leukemia: gilteritinib versus sorafenib
Phase 3 trial of MRD-guided maintenance after allogeneic transplant. The registry primary outcome is measurable residual disease recurrence-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 3 · Recruiting